Maus agrees: “I think we are definitely in a moment where this kind of science, this kind of potential product–engineered T cells–is transformational. They can be applied in so many different settings and diseases,” she says. But “I think it’s still a little bit early to know whether it’s going to be a commercial product for patients.”